Low-dose aspirin intake by hospitalized COVID-19 patients can reduce the risk of cardiovascular complications and death, reports a new study.

TOP INSIGHT
People relying on aspirin are less likely to be put on a ventilator and are more likely to survive the COVID-19 infection.
"This is a critical finding that needs to be confirmed through a randomized clinical trial," said study leader Jonathan Chow from the University of Maryland in the US.
"If our finding is confirmed, it will make aspirin the first widely available, over-the-counter medication to reduce mortality in Covid-19 patients," Chow added.
To conduct the study, the research team culled through the medical records of 412 Covid-19 patients, the age of 55 on average, who were hospitalized over the past few months due to complications of their infection.
About a quarter of the patients took a daily low-dose aspirin (usually 81 milligrams) before they were admitted or right after admission to manage their cardiovascular disease.
The aspirin group patients did not experience a significant increase in adverse events such as major bleeding while hospitalized.
Daily use, however, can increase the risk of major bleeding or peptic ulcer disease.
"We believe that the blood-thinning effects of aspirin provide benefits for Covid-19 patients by preventing micro clot formation," said study co-author Michael A Mazzeffi.
"Those at increased bleeding risk due to chronic kidney disease, for example, or because they regularly use certain medications, like steroids or blood thinners, may not be able to take aspirin safely," he added.
Source-IANS
MEDINDIA




Email










